Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Industry News
Features Subscription Partner Sites Journal Info
Veolia WATERRANDOX LABORATORIESAB SCIEX

Epigenomics Signs Nonexclusive Licensing Agreement for Septin9

By Labmedica International staff writers
Posted on 09 Jul 2012


Epigenomics AG (Berlin, Germany), a cancer molecular diagnostics company, signed a nonexclusive licensing agreement for its DNA methylation biomarker Septin9 with Companion Dx Reference Lab (Houston, TX, USA).

Under the terms of the agreement, Companion Dx has obtained rights to establish and commercialize a blood-based, laboratory-developed test (LDT) using methylated Septin9 as biomarker for the detection of colorectal cancer. Epigenomics is entitled to double digit royalties on sales.

The v2 region of the Sept9 promoter is methylated in colorectal cancer tissue compared with normal colonic mucosa. Using highly sensitive real time polymerase chain reaction (PCR) assays, methylated Sept9 was detected in the blood of colorectal cancer patients. This alternate methylation pattern in cancer samples is suggestive of an aberrant activation or repression of the gene compared to normal tissue samples.

The agreement with Companion Dx complements Epigenomics’ LDT agreements with Quest Diagnostics, (Madison, NJ, USA), Arup Laboratories (Salt Lake City, UT, USA), and Warnex Medical Laboratories (Laval, QC, Canada) in North America. In addition, Abbott Molecular (Des Plaines, IL, USA) has a worldwide, nonexclusive license to develop and to commercialize IVD test kit products while Qiagen (Hilden, Germany) and Sysmex (Kobe, Japan) have acquired options to do so.

Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of products for the screening and diagnosis of cancer. The company's lead product, Epi proColon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the USA.

Companion Dx Reference Lab specializes in pharmacogenomics testing and cancer companion diagnostics. Personalized pharmacogenomic evaluations reveal the patient's risks for serious side effects and reduced drug effectiveness, allowing the physician to make clinical decisions that improve therapeutic outcomes prior to therapy.

Related Links:
Epigenomics AG
Companion Dx Reference Lab








Cytology System
Cytology System
Chemistry Analyzer
Chemistry Analyzer
Viral Load Test
Viral Load Test

More Products

Latest Industry News News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
SIEMENS DIAGNOSTICS :
Siemens Healthcare Diagnostics Anti-CCP: A Clinical Evaluation Whitepaper

Download Whitepaper
Events
ELA – European Lab Automation congress
06 Jun 2013 - 07 Jun 2013


European Human Genetics Conference 2013
08 Jun 2013 - 11 Jun 2013


8th Forum on Oxidative Stress and Aging
12 Jun 2013 - 14 Jun 2013


More events
GLOBETECH PUBLISHING
Latest Issue

View Digital Edition
Subscribe / Renew
GREINER-BIO-ONE
AACC
DIASOURCE
BioPorto Diagnostics
ALTO MARKETING LIMITED
KARL HECHT GMBH & CO KG
77 ELEKTRONIKA
  labmedica.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy